-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
ADRIATIC Demonstrates Meaningful Improvements in OS, PFS in Patients with Limited-stage SCLC
As the first study to establish the role of immunotherapy in this setting, Dr. David R. Spigel says consolidation durvalumab will become the new standard of care for this population.
-
Patient Perspective: Exercise Prescriptions Needed for Lung Cancer Patients
Runner and patient advocate Angus Pratt says running three times a week may be the antithesis of what most people expect from a lung cancer patient, but not only is it possible, it is beneficial.
-
Glecirasib Shows Promise in Treating Advanced Lung Cancer Harboring KRAS G12C Mutations
With only 5% of patients stopping treatment due to treatment-related adverse events, lead author Yuankai Shi, MD, says glecirasib may help improve patient compliance with oral therapy.
-
US FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive-stage Small Cell Lung Cancer
The first-in-class immunotherapy offers a new option for SCLC patients with disease progression on or after platinum-based chemotherapy.
-
Mounting Evidence Supporting Neoadjuvant ChemoIO Means Surgeons Must Adapt
In a two-part commentary, Dr. Ke-Neng Chen discusses how surgeons must adjust in light of recent clinical trials, beginning with a discussion of the challenges of TNM staging.
-
More Than Ever, Surgeons Must Collaborate to Ensure Patients Receive Appropriate Care
As thoracic surgery in the management of NSCLC evolves, Dr. Ke-Neng Chen highlights the importance of avoiding unnecessary treatments and using a multidisciplinary approach.
-
A New Treatment Option for Early-Stage ALK+ NSCLC: Adjuvant Alectinib
In part 2 of their interview, Drs. Narjust Florez and Benjamin Solomon dig deeper into the implications of the ALINA trial, discussing endpoints, toxicities, and future directions.
-
European Commission OKs Tislelizumab for NSCLC
In other regulatory news, the US FDA recently granted a Breakthrough Therapy Designation for sunvozertinib for first-line treatment of advanced non-small cell lung cancer with EGFR Exon 20 Insertion mutations.
-
In Case You Missed It: Recent News from IASLC
Submit abstracts for ACLC 2024 by June 7, register for the 2024 CT Screening Symposium, and contribute memories for the 50th anniversary time capsule.
-
Increased Biomarker Uptake Needed to Further Realize Potential of Precision Medicine
Drs. Christian Rolfo and Valeria Denninghoff contend that data show improvements in outcomes from personalized treatment may have stalled and that increased testing for driver genes alterations is needed.